PRESCRIBING · PART D · 2024
Total Rx claims
112
Beneficiaries
—
Total drug cost
$1.2M
Distinct drugs
5
Brand share
62.5%
Top prescribed drugs
Ruxolitinib Phosphate40 claims
Hydroxyurea31 claims
Peginterferon Alfa-2a17 claims
Asciminib Hydrochloride13 claims
Deferasirox11 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
CROSS-REFERENCE